Sep 21, 2020 | News, Press Releases
Deeply Experienced Brand Marketer to Help Increase Awareness of CMT and Accelerate Research ATLANTA (September 21, 2020) The CMT Research Foundation, a nonprofit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease during our lifetime,...
Aug 17, 2020 | News, Press Releases
The CMT Research Foundation Adds Erich Fasnacht as Chief Operating Officer and Keith Fargo as Chief Scientific Officer Reinforces CMTRF’s Reputation as Preeminent Experts in CMT Research ATLANTA (August 17, 2020) The CMT Research Foundation (CMTRF), a nonprofit...
May 7, 2020 | Press Releases, Stories
By: Diane, CMT Patient I’d give you my feet if I could. That’s what my strong, stoic mother told me as she struggled to watch me walk as a teenager. I was a natural athlete growing up. I loved running and excelled at it. One day while running, I blew out my ankle....
Feb 12, 2020 | CMT Research Updates, CMTRF Funded Research, Drug Development, Press Releases, Research news
In February 2020, Dr. Kleopa completed milestone 2 of the 24-month project and the results continue to be encouraging. The goal during this 6-12 month period of the project was to further optimize the amount of PMP22 gene silencing in a mouse model of CMT1A. Dr....
Feb 12, 2020 | CMT Research Updates, CMTRF Funded Research, Drug Development, Gene Therapy, Press Releases
By Grace Pavlath, PhD By now you’ve likely heard that CMTRF is funding three genetic-based projects focused on therapy development for CMT1A: DTx Pharma, Shift Pharma and Cyprus Institute of Neurology and Genetics. Funding multiple complementary approaches gives...
Jan 30, 2020 | CMT Research Updates, CMTRF Funded Research, Drug Development, Press Releases, Research news
Shift to Develop and Analyze Novel Series of Drugs Designed to Control Expression of PMP22 Gene The CMT Research Foundation (CMTRF), a nonprofit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease, today announced it has partnered with...